Exact Mass: 505.3403

Exact Mass Matches: 505.3403

Found 31 metabolites which its exact mass value is equals to given mass value 505.3403, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Mycinamicin VIII

Mycinamicin VIII

C29H47NO6 (505.3403)


   

(4Z,7Z,10Z,13Z,16Z)-19,20-Dihydroxydocosa-4,7,10,13,16-pentaenoylcarnitine

3-[(19,20-dihydroxydocosa-4,7,10,13,16-pentaenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C29H47NO6 (505.3403)


(4Z,7Z,10Z,13Z,16Z)-19,20-dihydroxydocosa-4,7,10,13,16-pentaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z,16Z)-19,20-dihydroxydocosa-4,7,10,13,16-pentaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z,16Z)-19,20-dihydroxydocosa-4,7,10,13,16-pentaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z,16Z)-19,20-dihydroxydocosa-4,7,10,13,16-pentaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Cholylproline

1-(4-{5,9,16-trihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl}pentanoyl)pyrrolidine-2-carboxylic acid

C29H47NO6 (505.3403)


Cholylproline belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Cholylproline consists of the bile acid cholic acid conjugated to the amino acid Proline conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Cholylproline, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Cholylproline appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).

   
   

Coumingin|N-Acetyl-coumingidin|[3beta-(beta-Hydroxy-isovaleryloxy)-7-oxo-14alpha-methyl-podocarpanyliden-(13seqtrans)]-essigsaeure-(2-dimethylamino-aethylester)|[3beta-(beta-Hydroxy-isovaleryloxy)-7-oxo-14alpha-methyl-podocarpanyliden-(13xi)]-essigsaeure-[2-(acetyl-methyl-amino)-aethylester]|[3beta-(beta-hydroxy-isovaleryloxy)-7-oxo-14alpha-methyl-podocarpanylidene-(13seqtrans)]-acetic acid-(2-dimethylamino-ethyl ester)

Coumingin|N-Acetyl-coumingidin|[3beta-(beta-Hydroxy-isovaleryloxy)-7-oxo-14alpha-methyl-podocarpanyliden-(13seqtrans)]-essigsaeure-(2-dimethylamino-aethylester)|[3beta-(beta-Hydroxy-isovaleryloxy)-7-oxo-14alpha-methyl-podocarpanyliden-(13xi)]-essigsaeure-[2-(acetyl-methyl-amino)-aethylester]|[3beta-(beta-hydroxy-isovaleryloxy)-7-oxo-14alpha-methyl-podocarpanylidene-(13seqtrans)]-acetic acid-(2-dimethylamino-ethyl ester)

C29H47NO6 (505.3403)


   

1-[2-(trans-1,4-dihydroxycyclohexyl)ethyl] 8-[(4R*,4aS*,6R*,7S*,7aR*)-2,4,7-trimethyloctahydro-1H-cyclopenta[c]pyridin-6-yl] (2E,6E)-2,6-dimethylocta-2,6-dienedioate|incarvine F

1-[2-(trans-1,4-dihydroxycyclohexyl)ethyl] 8-[(4R*,4aS*,6R*,7S*,7aR*)-2,4,7-trimethyloctahydro-1H-cyclopenta[c]pyridin-6-yl] (2E,6E)-2,6-dimethylocta-2,6-dienedioate|incarvine F

C29H47NO6 (505.3403)


   

21F121-A

1-(2,4,12-trimethyl-2E,5Z,7Z,9Z,11Z-hexadecapentaenoyl)-sn-glycero-3-O-(N,N,N-trimethyl)-homoserine

C29H47NO6 (505.3403)


   

(4Z,7Z,10Z,13Z,16Z)-19,20-Dihydroxydocosa-4,7,10,13,16-pentaenoylcarnitine

(4Z,7Z,10Z,13Z,16Z)-19,20-Dihydroxydocosa-4,7,10,13,16-pentaenoylcarnitine

C29H47NO6 (505.3403)


   

(E)-3-hydroxy-2-(2-hydroxytetradecanoylamino)dodec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(2-hydroxytetradecanoylamino)dodec-4-ene-1-sulfonic acid

C26H51NO6S (505.3437)


   

3-hydroxy-2-[[(Z)-2-hydroxydodec-5-enoyl]amino]tetradecane-1-sulfonic acid

3-hydroxy-2-[[(Z)-2-hydroxydodec-5-enoyl]amino]tetradecane-1-sulfonic acid

C26H51NO6S (505.3437)


   

3-hydroxy-2-[[(Z)-2-hydroxyhexadec-7-enoyl]amino]decane-1-sulfonic acid

3-hydroxy-2-[[(Z)-2-hydroxyhexadec-7-enoyl]amino]decane-1-sulfonic acid

C26H51NO6S (505.3437)


   

(E)-3-hydroxy-2-(2-hydroxytridecanoylamino)tridec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(2-hydroxytridecanoylamino)tridec-4-ene-1-sulfonic acid

C26H51NO6S (505.3437)


   

(E)-3-hydroxy-2-(2-hydroxyhexadecanoylamino)dec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(2-hydroxyhexadecanoylamino)dec-4-ene-1-sulfonic acid

C26H51NO6S (505.3437)


   

3-hydroxy-2-[[(Z)-2-hydroxytetradec-9-enoyl]amino]dodecane-1-sulfonic acid

3-hydroxy-2-[[(Z)-2-hydroxytetradec-9-enoyl]amino]dodecane-1-sulfonic acid

C26H51NO6S (505.3437)


   

(E)-3-hydroxy-2-(2-hydroxypentadecanoylamino)undec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(2-hydroxypentadecanoylamino)undec-4-ene-1-sulfonic acid

C26H51NO6S (505.3437)


   

3-hydroxy-2-[[(Z)-2-hydroxytridec-8-enoyl]amino]tridecane-1-sulfonic acid

3-hydroxy-2-[[(Z)-2-hydroxytridec-8-enoyl]amino]tridecane-1-sulfonic acid

C26H51NO6S (505.3437)


   

3-hydroxy-2-[[(Z)-2-hydroxypentadec-9-enoyl]amino]undecane-1-sulfonic acid

3-hydroxy-2-[[(Z)-2-hydroxypentadec-9-enoyl]amino]undecane-1-sulfonic acid

C26H51NO6S (505.3437)


   

(E)-3-hydroxy-2-(2-hydroxydodecanoylamino)tetradec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(2-hydroxydodecanoylamino)tetradec-4-ene-1-sulfonic acid

C26H51NO6S (505.3437)


   

lysoDGTS 19:5

lysoDGTS 19:5

C29H47NO6 (505.3403)


   

2-[[(4E,8E)-2-(heptanoylamino)-3-hydroxytrideca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(4E,8E)-2-(heptanoylamino)-3-hydroxytrideca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C25H50N2O6P+ (505.3406)


   

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(propanoylamino)heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(propanoylamino)heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C25H50N2O6P+ (505.3406)


   

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(octanoylamino)dodeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(octanoylamino)dodeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C25H50N2O6P+ (505.3406)


   

2-[[(4E,8E)-2-acetamido-3-hydroxyoctadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(4E,8E)-2-acetamido-3-hydroxyoctadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C25H50N2O6P+ (505.3406)


   

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(pentanoylamino)pentadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(pentanoylamino)pentadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C25H50N2O6P+ (505.3406)


   

2-[[(4E,8E)-2-(butanoylamino)-3-hydroxyhexadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(4E,8E)-2-(butanoylamino)-3-hydroxyhexadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C25H50N2O6P+ (505.3406)


   

2-[[(4E,8E)-2-(hexanoylamino)-3-hydroxytetradeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(4E,8E)-2-(hexanoylamino)-3-hydroxytetradeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C25H50N2O6P+ (505.3406)


   
   

ST 27:2;O4;Gly

ST 27:2;O4;Gly

C29H47NO6 (505.3403)


   

ST 21:1;O;HexNAc

ST 21:1;O;HexNAc

C29H47NO6 (505.3403)


   

7-{2-[2-(dimethylamino)ethoxy]-2-oxoethylidene}-1,1,4a,8-tetramethyl-9-oxo-decahydrophenanthren-2-yl 3-hydroxy-3-methylbutanoate

7-{2-[2-(dimethylamino)ethoxy]-2-oxoethylidene}-1,1,4a,8-tetramethyl-9-oxo-decahydrophenanthren-2-yl 3-hydroxy-3-methylbutanoate

C29H47NO6 (505.3403)


   

(3e,5r,6r,7r,9r,11z,13e,15r,16r)-6-{[(2r,3s,4r,6s)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-16-ethyl-5,7,9,15-tetramethyl-1-oxacyclohexadeca-3,11,13-triene-2,10-dione

(3e,5r,6r,7r,9r,11z,13e,15r,16r)-6-{[(2r,3s,4r,6s)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-16-ethyl-5,7,9,15-tetramethyl-1-oxacyclohexadeca-3,11,13-triene-2,10-dione

C29H47NO6 (505.3403)